Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S G Holtan

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Bone Marrow Transplantation|June 6, 2017
Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402S G Holtan, L F Newell, C Cutler, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Leukemia|May 21, 2010
WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutationsM M Patnaik, T L Lasho, C M Finke, et al.
Bone Marrow Transplantation|October 24, 2017
Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402L M Turcotte, T E DeFor, L F Newell, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Bone Marrow Transplantation|June 6, 2017
Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402S G Holtan, L F Newell, C Cutler, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Leukemia|May 21, 2010
WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutationsM M Patnaik, T L Lasho, C M Finke, et al.
Bone Marrow Transplantation|October 24, 2017
Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402L M Turcotte, T E DeFor, L F Newell, et al.
Pageof 2